- Market Capitalization, $K 242,189
- Shares Outstanding, K 44,520
- Annual Sales, $ 133,250 K
- Annual Income, $ 17,140 K
- 60-Month Beta 1.02
- Price/Sales 1.84
- Price/Cash Flow 11.11
- Price/Book 1.37
|Period||Period Low||Period High||Performance|
| || |
-0.42 (-7.08%)since 06/28/21
| || |
-0.61 (-9.97%)since 04/28/21
| || |
-3.03 (-35.48%)since 07/28/20
Gilead's (GILD) wholly owned subsidiary Kite signs partnership deal with Shoreline Biosciences to develop novel cell therapies for cancer.
The FDA approves Blueprint Medicines' (BPMC) lead drug, Ayvakit, for treating adult patients with advanced systemic mastocytosis.
CRISPR Therapeutics (CRSP) signs a strategic collaboration with Capsida Biotherapeutics to develop/commercialize gene editing therapies for neurological diseases.
The FDA approves Vertex's (VRTX) triple combination therapy, Trikafta, for treating cystic fibrosis in children aged between six to 11 years.
The FDA bestows an Orphan Drug status to Arena's (ARNA) lead pipeline candidate, etrasimod, for the treatment of eosinophilic esophagitis.
The FDA approves Alexion's (ALXN) Ultomiris for the treatment of PNH in children of one month of age and older as well as adolescents.
The FDA lifts the clinical hold on bluebird's (BLUE) studies on LentiGlobin for sickle cell disease and betibeglogene autotemcel for transfusion-dependent thalassemia. Shares rise.
and REHOVOT, , /PRNewswire/ -- and Kamada Ltd. (NASDAQ: KMDA) and (TASE: KMDA), two leading biopharmaceutical companies specialized in plasma-derived protein therapeutics, announced today the U.S. Food...
Kamada (KMDA) delivered earnings and revenue surprises of 20.00% and -5.86%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
-- First Quarter 2021 Revenues were $24.9 Million, and Adjusted EBITDA was $3.7 Million
|Ark Israel Innovative Technology ETF|
|FTSE Developed Markets Vanguard|
|FTSE All-World Ex-US Smcp Idx ETF Vanguard|
|Total Intl Stock ETF Vanguard|
|Total World Stock Index ETF Vanguard|